查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1862520

乳癌篩檢市場按技術、年齡層、實施方式和最終用戶分類－2025-2032年全球預測

Breast Cancer Screening Market by Technology, Age Group, Delivery Mode, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，乳癌篩檢市場規模將達到 91.5 億美元，複合年成長率為 7.03%。

關鍵市場統計數據
基準年 2024 53.1億美元
預計年份：2025年 56.9億美元
預測年份 2032 91.5億美元
複合年成長率 (%) 7.03%

全面介紹不斷發展的乳癌篩檢模式，重點關注技術、政策、臨床實踐和以患者為中心的就醫趨勢。

乳癌篩檢處於技術創新、臨床指南、政策改革和患者期望不斷變化的交匯點，由此形成了一個動態環境，需要精準且基於實證醫學的決策。影像技術、軟體分析和醫療服務模式的進步正在重塑臨床醫生檢測和管理早期疾病的方式。同時，法規結構和支付方的優先事項也在不斷調整，以強調價值、療效和公平獲取。此外，不斷發展的宣傳宣傳活動和風險分層方法也推動了對更靈敏、更微創、更人性化的篩檢途徑的需求。

在此背景下，篩檢系統（包括製造商、醫院系統、門診中心、診斷連鎖機構、軟體供應商和支付方）必須應對各種相互衝突的壓力：一方面，需要採用高性能技術來提高診斷準確性；另一方面，需要控制成本並與電子工作流程相整合；此外，還需要證明其臨床效用和醫護人員的準備。技術融合，包括先進影像重建技術、多平面視覺化和智慧演算法的整合，正在加速以往僅限於三級醫療中心的影像技術在臨床上的應用。同時，雲端交付模式和軟體即服務 (SaaS) 選項正在降低高階分析技術的普及門檻，並促進遠距閱片和第二意見工作流程的發展。

本導言為深入探討轉型轉變、監管和貿易逆風、細分市場趨勢、區域差異、競爭行動以及旨在幫助高管、臨床領導、產品團隊和採購專家進行戰略規劃的實用建議奠定了基礎，這些建議旨在幫助他們的組織獲取臨床價值、支持可擴展的服務模式並改善患者路徑，同時不損害質量或合規性。

關鍵的變革性轉變正在加速臨床上對先進影像、人工智慧整合、個人化篩檢路徑和分散式雲端醫療模式的採用。

過去幾年，臨床實踐和市場動態發生了一系列變革性變化，重新定義了有效且公平的乳癌篩檢。其中最顯著的變化之一是容積成像和斷層成像技術在臨床實踐中的快速應用。這些技術與先進的後處理和閱片流程相結合，顯著提高了病灶的可見度，並降低了複檢率。影像技術的進步與人工智慧 (AI) 和機器學習演算法的成熟相輔相成，進一步提升了放射科醫師的診療水平，簡化了分診流程，並最佳化了分散式網路中有限診斷資源的分配。

另一個根本性的變化是篩檢路徑正朝著個人化、基於風險的方向發展。篩檢方案不再採用千篇一律的篩檢間隔或檢測方法，而是擴大根據臨床風險因素、遺傳易感性和既往影像檢查史等因素進行綜合調整。這促使人們更加關注針對特定族群的輔助檢測，例如對高風險族群進行對比造影磁振造影（MRI）檢查，以及對傳統乳房X光攝影受限的緻密型乳房族群採用分子成像技術。同時，檢測模式也在不斷發展。雲端對應平臺和軟體即服務（SaaS）產品正在加速進階分析的去中心化，並實現遠距離診斷；而自動化和照護現場硬體的改進則有助於擴大門診中心和社區診所的檢測覆蓋範圍。

勞動力轉型和臨床培訓也正在改變該領域的格局。隨著診斷影像變得日益複雜，對跨專業協作、標準化報告和健全的品質保證系統的需求也隨之增加。監管機構對互通性、資料隱私和臨床獲益證據的重視提高了新產品上市的標準，促使供應商提供更有力的真實世界證據，並更早與支付方接洽。這些變化正在塑造一個比以往更加技術主導、以患者為中心、更注重可驗證結果的篩檢環境。

美國關稅於2025年生效的累積影響：對採購、製造地、供應鏈韌性和軟體主導的臨床連續性的影響

2025年美國關稅政策對乳癌篩檢價值鏈產生了一系列累積效應，波及籌資策略、供應商選擇、製造地和臨床實施時間表。關鍵子系統（例如檢測器、數位影像擷取電子設備、專用幫浦線圈以及整合到先進成像平台中的半導體組件）進口成本的上升，迫使設備供應商重新評估供應鏈冗餘和組件採購。這些壓力促使一些製造商加快在地化生產並實現供應商多元化，同時壓縮產品藍圖，並優先考慮模組化升級而非系統級更新。

醫院、診斷中心和門診醫療機構的採購決策者正在積極應對，盡可能延長設備的使用壽命，並協商簽訂多年維護和升級協議，以緩解近期資本成本的成長。同時，規模較小的獨立診斷服務供應商正在探索替代交付模式，對雲端基礎的軟體訂閱和託管服務的需求日益成長，這些服務可以降低前期資本負擔。此外，關稅政策也凸顯了軟體主導的診斷增強功能的重要性，這些功能可以部署在現有硬體平台上，使醫療機構無需更換設備即可獲得額外的臨床價值。

監管機構和支付相關人員日益關注供應鏈中斷對醫療服務取得和篩檢計畫連續性的下游影響。為此，一些醫療系統優先投資於臨床培訓、跨平台相容性以及關鍵備件的緊急儲備，以維持服務的連續性。此外，關稅帶來的宏觀經濟訊號正在影響投資者和合作夥伴的行為，促使一些供應商重新評估其地理擴大策略，並在貿易條件更為有利的市場尋求製造合作夥伴關係。這導致製造商、服務供應商和醫療系統重新調整策略重點，更加強調韌性、軟體主導的差異化和靈活的採購模式。

可操作的細分洞察揭示了不同實踐環境中的特定模式發展軌跡、按年齡層分類的路徑、交付模式差異以及最終用戶採納趨勢

針對特定細分領域的趨勢對於理解整個乳癌篩檢流程中臨床價值的創造點以及推廣應用仍存在的障礙至關重要。技術細分揭示了清晰的推廣應用軌跡：2D乳房乳房X光攝影（包括類比和數位技術）仍然是基礎篩檢方式，而3D斷層合成技術正日益普及，以提高複雜乳房解剖結構的檢測精度。磁振造影造影（MRI）持續運作，根據患者風險狀況和臨床適應症，引入了造影通訊協定和非造影技術。分子乳房影像（包括專用乳房伽瑪成像和核子乳房攝影X光攝影）正作為輔助手段，在傳統X光方法難以處理的緻密組織病例中得到選擇性應用。熱成像和超音波發揮不同的作用，自動化超音波平台和攜帶式設備可作為互補的診斷手段，並有助於提高門診和社區醫療機構的可及性。

基於年齡的細分凸顯了差異化診療路徑的必要性。年輕患者和40歲以下的患者通常需要進行影像診斷，這主要是基於症狀評估或遺傳風險。而中年患者通常是篩檢的核心目標族群，其檢查選擇主要取決於乳房密度和先前影像檢查史。對於老年人而言，平衡過度診斷風險和敏感度面臨不同的挑戰，需要更細緻的共用決策流程。交付方式的細分正在影響部署和營運模式。對於高通量影像中心和綜合醫院系統而言，本地部署解決方案仍然至關重要。雲端解決方案，包括軟體即服務 (SaaS) 和基於 Web 的平台，能夠實現分散式閱片工作流程、集中式品管，並在無需大量資本支出的情況下逐步採用高級分析技術。最終使用者細分凸顯了不同醫療機構採用促進因素的差異：門診中心、基層醫療和專科診所、連鎖和獨立診斷中心以及公立和私立醫院的採購週期、臨床管治結構和報銷環境各不相同。了解這些組合細分層對於設計產品策略、臨床證據產生計劃和市場推廣方法至關重要，這些策略和方法應滿足每個相關利益者群體的需求和限制。

深入分析美洲、歐洲、中東和非洲以及亞太地區在採用模式、報銷環境和准入策略方面的差異化區域洞察

區域差異影響著醫療系統在乳癌篩檢領域採用的技術、報銷方式、人員配備和運作模式。在美洲，人們尤其重視將先進的篩檢能力集中在整合醫療網路和大型診斷連鎖機構中，同時，人們也越來越關注如何利用人工智慧驅動的閱片平台來管理大量患者並最佳化複檢率。該地區的市場動態受到支付方模式的影響，這些模式獎勵可驗證的療效，而集中式腫瘤計畫則推動了對高風險族群高靈敏度檢測的需求。

歐洲、中東和非洲地區呈現出多元化的格局，各國在監管標準、公共篩檢計畫結構和資源可用性方面存在顯著差異。在部分地區，有組織的群體篩選計畫和全民覆蓋模式正在加速標準化通訊協定和品質保證框架的採用；而在其他地區，基礎設施和人力資源的限制則推動了攜帶式、低成本檢測方法和遠端放射學服務的創新，以彌合服務獲取方面的差距。

亞太地區匯集了眾多實力雄厚的三級醫療中心，這些中心配備了最新的影像平台，同時社區層面的診斷服務也在迅速發展，優先考慮可及性和成本效益。在多個市場，公共衛生措施和不斷壯大的私部門正同步提升篩檢率，刺激了對雲端工作流程、人工智慧驅動的分診工具以及可在都市區和半都市區部署的可擴充性超音波解決方案的需求。在整個亞太地區，集中式專科醫療和分散式社區醫療之間的平衡將繼續影響投資重點和夥伴關係模式。

透過整合、模組化升級、臨床證據產生和雲端服務模式，實現企業級差異化策略洞察

乳癌篩檢生態系統的競爭動態由眾多參與者所構成，包括影像設備製造商、專業軟體供應商、雲端服務供應商、託管服務公司和臨床服務網路。領導企業憑藉整合解決方案脫穎而出，這些解決方案將硬體效能與先進的分析功能、強大的臨床證據包以及全生命週期服務能力相結合，從而降低整體擁有成本。設備製造商與軟體創新者之間的策略聯盟已成為加速人工智慧功能上市、並透過合作研究彌合臨床檢驗差距的有效途徑。

企業發展的另一個主要趨勢是注重模組化和可升級性，使客戶能夠在保留現有資本投資的同時，逐步採用更高級的功能。在資本支出預算受限且關稅相關的採購波動使得軟體主導的臨床改善更具吸引力的環境下，這種方法尤其受到青睞。服務供應商和閱片管理供應商正在利用雲端交付和訂閱模式，提供可擴展的閱片能力、集中式品質保證和效能分析，這些對大型醫院網路和獨立診斷中心都至關重要。

最後，企業策略越來越注重實際影響和展現與支付方相關的成果。投資前瞻性臨床研究、健康經濟學分析以及與領先臨床中心合作產生證據的公司，更有能力影響指南制定和支付方的核保決策。因此，我們看到，一些公司專注於功能上的漸進式改進，而另一些公司則追求深入的臨床檢驗和整合式護理路徑，以此作為持續差異化的手段，兩者之間出現了分化。

為行業領導者提供切實可行的建議，以推動技術應用、增強韌性並加速驗證其臨床和支付方價值。

產業領導者若想在乳癌篩檢領域維持並擴大其市場地位，應採取一系列務實且基於實證的行動，使商業性目標與臨床重點和營運實際情況相符。首先，應優先進行前瞻性多中心研究，以產生臨床證據，並以可靠的數據支持產品聲明，這些數據應反映診斷效能、工作流程效率和後續臨床影響，並與支付方的終點指標保持一致。其次，應採用模組化的產品和商業策略，使醫療機構能夠逐步升級軟體分​​析、人工智慧模組和雲端服務等功能，而無需徹底更換成像系統。這將降低採用門檻，並有助於維護客戶關係。

第三，透過多元化零件採購、探索區域製造夥伴關係以及開發服務模式來增強供應鏈韌性，從而最大限度地減少停機時間，並確保即使在中斷期間也能持續提供診斷服務。第四，加速培訓和變革管理專案的投資，以幫助放射科醫生、技術人員和轉診醫生整合新的技術和人工智慧輔助工作流程。這些投資將提高技術應用率、改善診斷一致性並提升患者滿意度。第五，積極與監管機構、指南委員會和支付方合作，共用真實世界證據，並制定以價值和結果而非檢測量為評估標準的報銷模式。第六，促進整個生態系統（包括學術機構、專科診所、診斷中心連鎖機構和技術合作夥伴）的策略合作，共同開發臨床路徑、試點新的護理模式，並在典型的臨床環境中檢驗價值提案。透過實施這些優先事項，產業領導者可以減少技術應用的障礙，展示可衡量的臨床效益，並確保其產品和服務在各種醫療保健環境中持續應用。

透過結合二手證據、相關人員檢驗和三角驗證的嚴謹混合調查方法，檢驗臨床和商業性發現。

本分析的調查方法結合了定性和定量方法，以確保所得出的洞見具有穩健性、可重複性，並能為整個生態系統中的決策者提供參考。該方法首先基於同行評審文獻、臨床指南、監管文件、專利概況和公司資訊披露進行全面的二手研究，以建立背景基礎並識別關鍵的技術、監管和報銷趨勢。隨後進行一手研究，包括與各類相關人員（放射科醫生、醫院採購負責人、診斷中心經理、技術供應商、支付方和臨床研究人員）進行結構化訪談和諮詢，檢驗假設、揭示應用促進因素並展現營運限制。

數據三角測量用於整合多元訊息，確保內部一致性。臨床聲明和產品特性與已發表的研究和專家意見進行交叉驗證。建立細分框架，並透過相關人員的檢驗進行迭代完善，以反映跨技術、人口統計、交付模式和最終用戶類型的真實決策流程。品質保證包括調查方法審核、與領域專家的同行評審以及對關鍵定性推論的敏感性檢查。最後，將研究結果綜合成可操作的敘述和策略要務，旨在支持採購決策、產品開發藍圖、臨床應用策略和政策參與舉措。

最終的綜合分析將整合技術、臨床和策略方面的必要因素，以幫助相關人員有效推廣篩檢並改善篩檢途徑。

總之，在技術進步、數據驅動型解決方案的興起以及強調個人化醫療和可衡量結果的臨床範式轉變的推動下，乳癌篩檢正在經歷一場深刻的變革時期。容積成像、人工智慧分析、多樣化的服務模式以及日益精細的證據要求，共同為價值鏈上的相關人員帶來了機會和挑戰。專注於模組化、循證解決方案並投資於人才培養和供應鏈韌性的醫療服務提供者和供應商，將更有能力將創新轉化為更早的檢測和患者預後的持續改善。

未來的策略重點應放在將新功能整合到現有臨床工作流程中，在相關患者群體中展現其相對臨床價值，並制定能夠反映長期治療效果和系統層面效率的採購和報銷框架。透過優先考慮臨床檢驗、靈活實施、兼顧區域特殊性以及與支付方和政策制定者開展務實合作，相關人員可以應對挑戰，擴大高性能篩檢方法的普及範圍，最終促進不同醫療體系中疾病的早期發現和患者預後的改善。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將人工智慧驅動的乳房X光攝影演算法應用於臨床，以提高診斷準確率並減少假陽性結果
  • 採用造影乳房X光攝影技術，以便更精確地顯示緻密乳房組織中的腫瘤
  • 拓展液態生物檢體篩檢，用於非侵入性檢測早期乳癌生物標記物
  • 透過在服務不足地區引入攜帶式超音波系統，改善即時乳房攝影服務的可及性
  • 開發用於乳癌篩檢中循環腫瘤DNA分析的自採集套件
  • 政府採取措施，為高風險族群引入基於風險的個人化篩檢方案
  • 整合遠距乳房X光檢查平台，以促進農村醫療機構的遠距專家會診
  • 一種基於深度學習的分流工具應運而生，旨在優先處理異常乳房X光攝影，從而減輕放射科醫師的工作量。
  • 實施以價值為導向的報銷模式，以促進早期發現和高品質篩檢
  • 疫情後篩檢延誤消除計畫：利用移動式乳房X光檢查車解決篩檢延誤問題的措施

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章乳癌篩檢市場（依技術分類）

  • 2D乳房X光攝影
    • 模擬
    • 數位的
  • 3D斷層合成
  • 磁振造影
    • 使用造影
    • 非造影
  • 分子乳腺影像
    • 專用乳房伽瑪成像
    • 核子乳房攝影
  • 熱成像
  • 超音波
    • 自動化
    • 手持式

第9章 按年齡層別分類的乳癌篩檢市場

  • 40-49歲
  • 50至69歲
  • 70歲或以上
  • 40歲以下

第10章 以交付方式乳癌篩檢市場

  • 雲
    • 軟體即服務
    • 基於網路的
  • 本地部署

第11章乳癌篩檢市場（依最終用戶分類）

  • 門診治療中心
  • 診所
    • 基層醫療診所
    • 專科診所
  • 診斷中心
    • 連鎖中心
    • 獨立中心
  • 醫院
    • 私立醫院
    • 公立醫院

第12章 各地區乳癌篩檢市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章乳癌篩檢市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國乳癌篩檢市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Hologic, Inc.
    • GE HealthCare
    • Siemens Healthineers AG
    • Koninklijke Philips NV
    • Fujifilm Holdings Corporation
    • Canon Medical Systems Corporation
    • Konica Minolta, Inc.
    • Shimadzu Corporation
    • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    • Carestream Health, Inc.
Product Code: MRR-521BAA36EB3C

The Breast Cancer Screening Market is projected to grow by USD 9.15 billion at a CAGR of 7.03% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.31 billion
Estimated Year [2025] USD 5.69 billion
Forecast Year [2032] USD 9.15 billion
CAGR (%) 7.03%

Comprehensive introduction to evolving breast cancer screening paradigms highlighting technology, policy, clinical practice and patient-centric access dynamics

Breast cancer screening is at the intersection of technological innovation, clinical guidelines, policy reform, and shifting patient expectations, creating a dynamic environment that demands precise, evidence-based decision making. Advances in imaging modalities, software analytics, and care delivery models are reshaping how clinicians detect and manage early-stage disease, while regulatory frameworks and payer priorities are aligning to emphasize value, outcomes, and equitable access. Concurrently, evolving awareness campaigns and risk-stratified approaches have intensified demand for more sensitive, less invasive, and patient-friendly screening pathways.

Against this backdrop, the ecosystem that supports screening-manufacturers, hospital systems, ambulatory centers, diagnostic chains, software vendors, and payers-must reconcile competing pressures: the need to adopt high-performance technologies that improve diagnostic accuracy, the imperative to control costs and integrate with electronic workflows, and the requirement to demonstrate clinical utility and workforce readiness. Technological convergence, including the integration of advanced image reconstruction, multiplanar visualization, and intelligent algorithms, is accelerating the clinical uptake of modalities that were once confined to tertiary centers. Meanwhile, cloud-enabled delivery modes and software-as-a-service options are lowering barriers to deployment of advanced analytics and facilitating remote reading and second-opinion workflows.

The introduction sets the stage for a detailed exploration of transformational shifts, regulatory and trade headwinds, segmentation-specific dynamics, regional differentiation, competitive behavior, and pragmatic recommendations. It is designed to inform strategic planning by executives, clinical leaders, product teams, and procurement specialists seeking to position their organizations to capture clinical value, support scalable service models, and improve patient pathways without compromising on quality or compliance.

Pivotal transformative shifts accelerating clinical adoption of advanced imaging, AI integration, personalized screening pathways and distributed cloud-enabled care models

The past few years have produced a series of transformative shifts that are redefining what effective and equitable breast cancer screening looks like in clinical practice and in market dynamics. One of the most consequential shifts is the rapid clinical adoption of volumetric and tomographic imaging techniques, which when combined with sophisticated post-processing and reading workflows, have materially improved lesion conspicuity and reduced recall rates. These imaging advances are complemented by the maturation of artificial intelligence and machine learning algorithms that augment radiologist performance, streamline triage pathways, and optimize the allocation of scarce diagnostic expertise across distributed networks.

Another foundational shift is the movement toward personalized, risk-based screening pathways. Rather than one-size-fits-all intervals and modalities, screening programs are increasingly calibrated using a combination of clinical risk factors, genetic predispositions, and prior imaging history. This has catalyzed interest in adjunctive modalities for selected cohorts, including contrast-enhanced MRI for high-risk individuals and molecular imaging techniques for dense-breast populations where traditional mammography has limitations. In parallel, delivery models are evolving: cloud-enabled platforms and software-as-a-service offerings have accelerated the decentralization of advanced analytics and enabled remote interpretation, while automated and point-of-care hardware variants are expanding access in ambulatory centers and community clinics.

Workforce transformation and clinical training are also reshaping the landscape. As imaging complexity grows, so does the need for multidisciplinary collaboration, standardized reporting, and robust quality assurance programs. Regulatory emphasis on interoperability, data privacy, and evidence of clinical benefit has heightened the bar for new product adoption, incentivizing vendors to generate stronger real-world evidence and to engage payers earlier. Collectively, these shifts are creating a screening ecosystem that is more technology-driven, more patient-centric, and more focused on demonstrable outcomes than in previous eras.

Cumulative implications of United States tariffs enacted in 2025 on procurement, manufacturing footprints, supply chain resilience and software-led clinical continuity

The imposition of tariffs by the United States in 2025 has introduced a set of cumulative effects that are reverberating across the breast cancer screening value chain, influencing procurement strategies, vendor sourcing, manufacturing footprints, and clinical adoption timelines. Increased import costs for key subsystems, such as detectors, digital acquisition electronics, specialized pumps and coils, and the semiconductor components embedded in advanced imaging platforms, have pressured equipment vendors to rethink supply chain redundancy and component sourcing. These pressures have incentivized some manufacturers to accelerate regional manufacturing or supplier diversification while compressing product roadmaps to prioritize modular upgrades over full-system replacements.

Procurement decision-makers within hospitals, diagnostic centers, and ambulatory care settings have responded by extending equipment life cycles where clinically feasible and by negotiating multi-year service and upgrade agreements that can mitigate near-term capital cost inflation. At the same time, smaller and independent diagnostic operators have sought alternative delivery models, shifting demand toward cloud-based software subscriptions and managed services that reduce upfront capital exposure. The tariffs have also amplified the importance of software-driven diagnostic enhancements that can be deployed on existing hardware platforms, enabling providers to extract incremental clinical value without undertaking full equipment replacements.

Regulatory and payer stakeholders have become more attentive to the downstream implications of supply chain disruptions on access to care and the consistency of screening programs. In response, some health systems have prioritized investments in clinical training, cross-platform compatibility, and contingency stocking of critical spare parts to preserve service continuity. Finally, the macroeconomic signal sent by tariffs has affected investor and partnership behavior, prompting some vendors to reassess geographic expansion strategies and to seek manufacturing collaborations in markets with more favorable trade terms. The net effect is a reconfiguration of strategic priorities across manufacturers, service providers, and health systems that emphasizes resilience, software-led differentiation, and flexible procurement models.

Actionable segmentation insights revealing modality-specific trajectories, age-tailored pathways, delivery-mode differentiation and end-user adoption dynamics across care settings

Segment-specific dynamics are crucial for understanding where clinical value is created and where adoption friction persists across the breast cancer screening continuum. Technology segmentation reveals distinct adoption trajectories: two-dimensional mammography remains a foundational screening modality with analog and digital variants still in operation alongside the increasing uptake of three-dimensional tomosynthesis for improved detection in complex breast anatomy. Magnetic resonance imaging continues to diversify with contrast-enhanced protocols and non-contrast techniques being deployed according to patient risk profiles and clinical indications. Molecular breast imaging, including breast-specific gamma imaging and scintimammography, is gaining selective traction as an adjunct in cases of dense tissue where traditional x-ray-based modalities are challenged. Thermography and ultrasound modalities present differentiated roles; automated ultrasound platforms and handheld devices serve complementary diagnostic purposes and extend access in ambulatory and community settings.

Age group segmentation underscores the need for differentiated pathways: younger cohorts and those under forty often require diagnostic-focused imaging due to symptom-driven evaluation and genetic risk, while middle-aged groups typically represent the core screening population with modality selection influenced by breast density and prior imaging history. Older cohorts may face different trade-offs between sensitivity and the risks associated with overdiagnosis, necessitating nuanced shared decision-making processes. Delivery-mode segmentation is shaping deployment and operational models: on-premise solutions remain essential for high-throughput imaging centers and integrated hospital systems, whereas cloud-based offerings, including software-as-a-service and web-based platforms, are enabling distributed reading workflows, centralized quality control, and incremental adoption of advanced analytics without significant capital outlay. End-user segmentation highlights the different adoption drivers across care settings: ambulatory care centers, clinics-both primary care and specialty clinics-diagnostic centers, whether chain or independent, and hospitals, both public and private, each operate under distinct procurement cycles, clinical governance structures, and reimbursement environments. Understanding these segmentation layers in combination is essential for designing product strategies, clinical evidence generation plans, and go-to-market approaches that align with the needs and constraints of each stakeholder group.

Key regional insights on differentiated adoption patterns, reimbursement environments and access strategies across Americas, EMEA and Asia-Pacific

Regional differentiation influences technology adoption, reimbursement approaches, workforce availability, and the operational models that health systems deploy for breast cancer screening. In the Americas, there is a pronounced emphasis on consolidating advanced screening capabilities within integrated delivery networks and large diagnostic chains, coupled with growing interest in deploying AI-enabled reading platforms to manage high patient volumes and optimize recall rates. Market dynamics in this region are shaped by payer models that reward demonstrable outcomes and by centralized oncology programs that drive demand for high-sensitivity modalities in high-risk populations.

The Europe, Middle East & Africa region presents a heterogeneous landscape where regulatory standards, public screening program structures, and resource availability vary widely across national jurisdictions. In parts of this region, organized population-based screening programs and universal coverage models have accelerated the adoption of standardized protocols and quality assurance frameworks, while in others, infrastructure and workforce constraints have fostered innovation in portable, lower-cost modalities and tele-radiology services that bridge gaps in access.

Asia-Pacific demonstrates a blend of high-capacity tertiary centers equipped with the latest imaging platforms and rapidly expanding community-level diagnostic services that prioritize accessibility and cost-effectiveness. In several markets, public health initiatives and private sector expansion are simultaneously increasing screening uptake, which in turn has stimulated demand for cloud-enabled workflows, AI-driven triage tools, and scalable ultrasound solutions that can be deployed in both urban and semi-urban contexts. Across regions, the balance between centralized specialist services and decentralized community access will continue to shape investment priorities and partnership models.

Strategic company-level insights on differentiation through integration, modular upgradability, clinical evidence generation and cloud-enabled service models

Competitive dynamics in the breast cancer screening ecosystem are defined by a diverse set of participants spanning imaging equipment manufacturers, specialized software vendors, cloud service providers, managed service firms, and clinical service networks. Leaders are differentiating through integrated solutions that combine hardware performance with advanced analytics, robust clinical evidence packages, and lifecycle service capabilities that reduce total cost of ownership. Strategic partnerships between device manufacturers and software innovators have become an effective route to accelerate time-to-market for AI-enabled features and to bridge clinical validation gaps through collaborative studies.

Another important trend among companies is the emphasis on modularity and upgradability, which allows customers to incrementally adopt advanced capabilities while preserving existing capital investments. This approach has been particularly attractive in environments where capital budgets are constrained or where tariff-related procurement volatility has heightened the appeal of software-driven clinical improvement. Service providers and managed-read vendors are capitalizing on cloud delivery and subscription models to offer scalable reading capacity, centralized quality assurance, and performance analytics that are valuable to both large hospital networks and independent diagnostic centers.

Finally, corporate strategies are increasingly focused on demonstrating real-world clinical impact and payer-relevant outcomes. Companies that invest in prospective clinical studies, health-economic analyses, and collaborative evidence generation with leading clinical centers are better positioned to influence guideline development and payer coverage decisions. As a result, a bifurcation is emerging between firms that emphasize incremental feature improvements and those that pursue deeper clinical validation and integrated care pathways as a route to sustained differentiation.

Practical and actionable recommendations for industry leaders to accelerate adoption, build resilience, and demonstrate clinical and payer-relevant value

Industry leaders seeking to maintain and grow their positions in the breast cancer screening arena should pursue a set of pragmatic, evidence-driven actions that align commercial objectives with clinical priorities and operational realities. First, prioritize clinical evidence generation that is prospective, multi-center, and aligned to payer endpoints so that product claims are supported by robust data demonstrating diagnostic performance, workflow efficiency, and downstream clinical impact. Second, adopt a modular product and commercial strategy that enables providers to incrementally upgrade capabilities-software analytics, AI modules, and cloud services-without requiring wholesale replacement of imaging systems, thereby lowering adoption barriers and preserving customer relationships.

Third, strengthen supply chain resilience by diversifying component sourcing, exploring regional manufacturing partnerships, and developing service models that minimize downtime and ensure continuity of diagnostic services during disruptions. Fourth, invest in training and change management programs that support radiologists, technologists, and referring clinicians in integrating new modalities and AI-assisted workflows; such investments accelerate adoption, improve diagnostic consistency, and enhance patient satisfaction. Fifth, actively engage with regulatory bodies, guideline committees, and payers to communicate real-world evidence and to shape reimbursement paradigms that reward value and outcomes rather than procedural volume. Sixth, pursue strategic collaborations across the ecosystem-academic centers, specialty clinics, chains of diagnostic centers, and technology partners-to co-develop clinical pathways, pilot new care models, and validate value propositions in representative clinical environments. By executing on these priorities, industry leaders can reduce friction in adoption, demonstrate measurable clinical benefit, and position their offerings for sustainable uptake across diverse care settings.

Rigorous mixed-methods research methodology combining secondary evidence, stakeholder interviews and triangulation to validate clinical and commercial insights

The research methodology underpinning this analysis combines qualitative and quantitative approaches to ensure that insights are robust, replicable, and relevant to decision-makers across the ecosystem. The approach begins with comprehensive secondary research drawing from peer-reviewed literature, clinical guidelines, regulatory filings, patent landscapes, and company disclosures to build a contextual foundation and identify key technology, regulatory, and reimbursement trends. This is followed by primary research, including structured interviews and consultations with a cross-section of stakeholders such as radiologists, hospital procurement officers, diagnostic center managers, technology vendors, payers, and clinical investigators, to validate assumptions, uncover adoption drivers, and surface operational constraints.

Data triangulation is applied to reconcile diverse inputs and to ensure internal consistency; clinical claims and product capabilities are cross-referenced with published studies and expert commentary. Segmentation frameworks are developed and iteratively refined through stakeholder validation to reflect real-world decision processes across technology, age cohorts, delivery modes, and end-user types. Quality assurance includes methodological audits, peer review by subject-matter experts, and sensitivity checks on key qualitative inferences. Finally, findings are synthesized into actionable narratives and strategic imperatives that are designed to support procurement decisions, product development roadmaps, clinical adoption strategies, and policy engagement initiatives.

Concluding synthesis that integrates technological, clinical and strategic imperatives to guide stakeholders toward impactful screening adoption and access improvements

In conclusion, breast cancer screening is undergoing a period of substantive transformation driven by technological advancement, the ascendancy of data-driven solutions, and evolving clinical paradigms that emphasize personalized care and measurable outcomes. The confluence of volumetric imaging, AI-enabled analytics, diversified delivery models, and increasingly sophisticated evidence expectations has created both opportunities and challenges for stakeholders across the value chain. Providers and vendors that align around modular, evidence-backed solutions and invest in workforce readiness and supply chain resilience will be best positioned to translate innovation into sustained improvements in early detection and patient outcomes.

Looking forward, the strategic focus should remain on integrating new capabilities within existing clinical workflows, demonstrating comparative clinical value in relevant patient cohorts, and crafting procurement and reimbursement narratives that reflect long-term outcomes and system-level efficiencies. By prioritizing these elements-clinical validation, flexible deployment, regional sensitivity, and pragmatic engagement with payers and policymakers-stakeholders can navigate trade headwinds, scale access to high-performance screening modalities, and ultimately contribute to earlier detection and better patient trajectories across diverse health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Clinical integration of AI-powered mammography algorithms to improve diagnostic accuracy and reduce false positives
  • 5.2. Adoption of contrast-enhanced mammography techniques for more precise tumor visualization in dense breast tissue
  • 5.3. Expansion of liquid biopsy screening solutions for noninvasive detection of early-stage breast cancer biomarkers
  • 5.4. Deployment of portable ultrasound systems in underserved regions to enhance access to real-time breast imaging
  • 5.5. Development of home-based self-sampling kits for circulating tumor DNA analysis in breast cancer screening
  • 5.6. Government initiatives to implement risk-based personalized screening schedules for high-risk populations
  • 5.7. Integration of telemammography platforms to facilitate remote expert consultations in rural healthcare settings
  • 5.8. Emergence of deep learning triage tools for prioritizing abnormal mammograms and reducing radiologist workload
  • 5.9. Implementation of value-based reimbursement models incentivizing early detection and quality of breast cancer screening
  • 5.10. Post-pandemic screening catch-up programs leveraging mobile mammography units to address screening backlogs

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Breast Cancer Screening Market, by Technology

  • 8.1. 2D Mammography
    • 8.1.1. Analog
    • 8.1.2. Digital
  • 8.2. 3D Tomosynthesis
  • 8.3. Magnetic Resonance Imaging
    • 8.3.1. Contrast Enhanced
    • 8.3.2. Non Contrast
  • 8.4. Molecular Breast Imaging
    • 8.4.1. Breast Specific Gamma Imaging
    • 8.4.2. Scintimammography
  • 8.5. Thermography
  • 8.6. Ultrasound
    • 8.6.1. Automated
    • 8.6.2. Handheld

9. Breast Cancer Screening Market, by Age Group

  • 9.1. 40 To 49
  • 9.2. 50 To 69
  • 9.3. 70 And Above
  • 9.4. Under 40

10. Breast Cancer Screening Market, by Delivery Mode

  • 10.1. Cloud
    • 10.1.1. Software As A Service
    • 10.1.2. Web Based
  • 10.2. On Premise

11. Breast Cancer Screening Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Clinics
    • 11.2.1. Primary Care Clinics
    • 11.2.2. Specialty Clinics
  • 11.3. Diagnostic Centers
    • 11.3.1. Chain Centers
    • 11.3.2. Independent Centers
  • 11.4. Hospitals
    • 11.4.1. Private Hospitals
    • 11.4.2. Public Hospitals

12. Breast Cancer Screening Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Breast Cancer Screening Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Breast Cancer Screening Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Hologic, Inc.
    • 15.3.2. GE HealthCare
    • 15.3.3. Siemens Healthineers AG
    • 15.3.4. Koninklijke Philips N.V.
    • 15.3.5. Fujifilm Holdings Corporation
    • 15.3.6. Canon Medical Systems Corporation
    • 15.3.7. Konica Minolta, Inc.
    • 15.3.8. Shimadzu Corporation
    • 15.3.9. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
    • 15.3.10. Carestream Health, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BREAST CANCER SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BREAST CANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. BREAST CANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BREAST CANCER SCREENING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BREAST CANCER SCREENING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BREAST CANCER SCREENING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ANALOG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ANALOG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ANALOG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ANALOG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ANALOG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ANALOG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIGITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIGITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIGITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIGITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIGITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIGITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 3D TOMOSYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 3D TOMOSYNTHESIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 3D TOMOSYNTHESIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 3D TOMOSYNTHESIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 3D TOMOSYNTHESIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 3D TOMOSYNTHESIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CONTRAST ENHANCED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CONTRAST ENHANCED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CONTRAST ENHANCED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CONTRAST ENHANCED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CONTRAST ENHANCED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CONTRAST ENHANCED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY NON CONTRAST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY NON CONTRAST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY NON CONTRAST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY NON CONTRAST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY NON CONTRAST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY NON CONTRAST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BREAST SPECIFIC GAMMA IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BREAST SPECIFIC GAMMA IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BREAST SPECIFIC GAMMA IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BREAST SPECIFIC GAMMA IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BREAST SPECIFIC GAMMA IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY BREAST SPECIFIC GAMMA IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SCINTIMAMMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SCINTIMAMMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SCINTIMAMMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SCINTIMAMMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SCINTIMAMMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SCINTIMAMMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY THERMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AUTOMATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AUTOMATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AUTOMATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AUTOMATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AUTOMATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AUTOMATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HANDHELD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HANDHELD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HANDHELD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HANDHELD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HANDHELD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HANDHELD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 40 TO 49, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 40 TO 49, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 40 TO 49, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 40 TO 49, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 40 TO 49, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 40 TO 49, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 50 TO 69, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 50 TO 69, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 50 TO 69, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 50 TO 69, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 50 TO 69, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 50 TO 69, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 70 AND ABOVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 70 AND ABOVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 70 AND ABOVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 70 AND ABOVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 70 AND ABOVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY 70 AND ABOVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY UNDER 40, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY UNDER 40, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY UNDER 40, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY UNDER 40, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY UNDER 40, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY UNDER 40, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SOFTWARE AS A SERVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SOFTWARE AS A SERVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SOFTWARE AS A SERVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SOFTWARE AS A SERVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SOFTWARE AS A SERVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SOFTWARE AS A SERVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY WEB BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY WEB BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY WEB BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY WEB BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY WEB BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY WEB BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ON PREMISE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ON PREMISE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ON PREMISE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ON PREMISE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ON PREMISE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY ON PREMISE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIMARY CARE CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIMARY CARE CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIMARY CARE CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIMARY CARE CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CHAIN CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CHAIN CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CHAIN CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CHAIN CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CHAIN CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY CHAIN CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY INDEPENDENT CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY INDEPENDENT CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY INDEPENDENT CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY INDEPENDENT CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY INDEPENDENT CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY INDEPENDENT CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BREAST CANCER SCREENING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY DELIVERY MODE, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY CLOUD, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2018-2024 (USD MILLION)
  • TABLE 298. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA BREAST CANCER SCREENING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY 2D MAMMOGRAPHY, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING, 2025-2032 (USD MILLION)

TABLE 311.